Literature DB >> 34959082

Antiviral immunity triggered by infection-induced host transposable elements.

Benjamin G Hale1.   

Abstract

Host silencing of transposable elements (TEs) is critical to prevent genome damage and inappropriate inflammation. However, new evidence suggests that a virus-infected host may re-activate TEs and co-opt them for antiviral defense. RNA-Seq and specialized bioinformatics have revealed the diversity of virus infections that induce TEs. Furthermore, studies with influenza virus have uncovered how infection-triggered changes to the SUMOylation of TRIM28, an epigenetic co-repressor, lead to TE de-repression. Importantly, there is a growing appreciation of how de-repressed TEs stimulate antiviral gene expression, either via cis-acting enhancer functions or via their recognition as viral mimetics by innate immune nucleic acid sensors (e.g. RIG-I, mda-5 and cGAS). Understanding how viruses trigger, and counteract, TE-based antiviral immunity should provide insights into pathogenic mechanisms.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34959082     DOI: 10.1016/j.coviro.2021.12.006

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  3 in total

1.  Editorial overview: 2022 "Virus-Host Interaction" section of Current Opinion in Virology.

Authors:  Michaela U Gack; Susan C Baker
Journal:  Curr Opin Virol       Date:  2022-05-23       Impact factor: 7.121

2.  Influenza A Virus Infection Reactivates Human Endogenous Retroviruses Associated with Modulation of Antiviral Immunity.

Authors:  Hengyuan Liu; Valter Bergant; Goar Frishman; Andreas Ruepp; Andreas Pichlmair; Michelle Vincendeau; Dmitrij Frishman
Journal:  Viruses       Date:  2022-07-21       Impact factor: 5.818

3.  Impaired activation of transposable elements in SARS-CoV-2 infection.

Authors:  Matan Sorek; Eran Meshorer; Sharon Schlesinger
Journal:  EMBO Rep       Date:  2022-08-16       Impact factor: 9.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.